247 related articles for article (PubMed ID: 7683356)
1. In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients.
Gattei V; Aldinucci D; Petti MC; Da Ponte A; Zagonel V; Pinto A
Leukemia; 1993 May; 7 Suppl 1():42-8. PubMed ID: 7683356
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the blast self-renewal capacity in patients with acute myeloid leukemia.
Nara N; Kurokawa H; Tanikawa S; Tomiyama J; Nagata K
Cancer; 1994 Jan; 73(1):92-7. PubMed ID: 8275443
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Yang GS; McCulloch EA
Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
[TBL] [Abstract][Full Text] [Related]
4. Effects of recombinant human tumor necrosis factor on the self-renewal capacity of leukemia blast progenitors in acute myeloblastic leukemia.
Nagata K; Tohda S; Suzuki T; Nara N
Leukemia; 1989 Sep; 3(9):626-30. PubMed ID: 2761317
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.
Petti MC; Mandelli F; Zagonel V; De Gregoris C; Merola MC; Latagliata R; Gattei V; Fazi P; Monfardini S; Pinto A
Leukemia; 1993 May; 7 Suppl 1():36-41. PubMed ID: 7683355
[TBL] [Abstract][Full Text] [Related]
6. Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Ryningen A; Stapnes C; Bruserud Ø
Leuk Res; 2007 Sep; 31(9):1303-13. PubMed ID: 17416413
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of 4-hydroperoxycyclophosphamide for the blast progenitors of acute myeloblastic leukemia.
Nara N; Suzuki T; Yamashita Y; Murohashi I; Aoki N
Cancer Res; 1988 May; 48(9):2348-52. PubMed ID: 3162711
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site-selective 8-chloroadenosine 3',5'-cyclic monophosphate.
Pinto A; Aldinucci D; Gattei V; Zagonel V; Tortora G; Budillon A; Cho-Chung YS
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):8884-8. PubMed ID: 1329084
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the in vitro growth of blast progenitors from acute myeloblastic leukemia patients by transforming growth factor-beta (TGF-beta).
Nara N; Tohda S; Nagata K; Suzuki T; Yamashita Y
Leukemia; 1989 Aug; 3(8):572-7. PubMed ID: 2473359
[TBL] [Abstract][Full Text] [Related]
10. The in vitro growth patterns and drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia.
Nara N; Chen GJ; Murohashi I; Tohda S; Imai Y; Tomiyama J; Nagata K; Suzuki T; Tanikawa S; Shiina S
Exp Hematol; 1992 Aug; 20(7):904-8. PubMed ID: 1628709
[TBL] [Abstract][Full Text] [Related]
11. The role of decitabine for the treatment of acute myeloid leukemia.
Ganetsky A
Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
[TBL] [Abstract][Full Text] [Related]
12. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
Momparler RL; Doré BT; Labiberté J; Momparler LF
Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of hematopoietic progenitors of acute myeloblastic leukemia to new compounds derived from marine organisms.
Lishner M; Shur I; Bleiberg I; Rudi A; Kashman Y; Fabian I
Leukemia; 1995 Sep; 9(9):1543-8. PubMed ID: 7658723
[TBL] [Abstract][Full Text] [Related]
14. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
16. Growth modulation and differentiation of acute myeloid leukemia cells by jaspamide.
Fabian I; Shur I; Bleiberg I; Rudi A; Kashman Y; Lishner M
Exp Hematol; 1995 Jul; 23(7):583-7. PubMed ID: 7601248
[TBL] [Abstract][Full Text] [Related]
17. Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia.
Estrov Z; Estey EH; Andreeff M; Talpaz M; Kurzrock R; Reading CL; Deisseroth AB; Gutterman JU
Exp Hematol; 1992 Jun; 20(5):558-64. PubMed ID: 1587302
[TBL] [Abstract][Full Text] [Related]
18. Response to 5-azacytidine of leukemic blast cells in suspension: a biological parameter associated with response to chemotherapy.
Wang C; Curtis JE; Senn JS; Tritchler DL; McCulloch EA
Leukemia; 1987 Nov; 1(11):753-6. PubMed ID: 2446086
[TBL] [Abstract][Full Text] [Related]
19. Effect of recombinant human M-CSF on the proliferation of leukemic blast progenitors in AML patients.
Suzuki T; Nagata K; Murohashi I; Nara N
Leukemia; 1988 Jun; 2(6):358-62. PubMed ID: 3287022
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Momparler RL; Côté S; Momparler LF
Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
